Feb 7 2010
D3 Technologies Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface-Enhanced Raman Scattering (SERS) and Surface-Enhanced Resonance Raman Scattering (SERRS), today announced that it has appointed David Burns as its new Chief Executive Officer.
David Burns, new CEO of D3 Technologies Ltd
He will lead the Company towards the international launch of its first in-vitro diagnostic (IVD) products, with the aim to establish D3 Technologies as a global player in the field of molecular diagnostics for human infectious diseases. Mr Burns has over 20 years of commercial life sciences experience, most recently as VP of Sales & Marketing with Cyntellect Inc, and before that as Head of Strategic Growth with GE Healthcare Life Sciences.
The Company’s current CEO, Professor Ewen Smith, is standing down to focus on the technical development of the exciting portfolio of diagnostics products that D3 Technologies has targeted for the next few years. Speaking about the new appointment he said, “I am delighted to welcome David to the Company. We already have a strong multi-disciplinary technical team and with his proven leadership skills, international experience of the clinical molecular diagnostics market and excellent track record in business development, the future is very bright for D3 Technologies.”
Mr Burns has gained extensive knowledge of sales, marketing and business development within the life sciences sector. Prior to GE Healthcare he also held senior roles within Amersham Biosciences, was CEO at Imaging Research Inc before its acquisition by Amersham, and VP of Business Development at BioSignal Packard Inc. “I am very excited by this new challenge,” said Mr Burns. “D3 Technologies has a tremendous future and I am looking forward to helping the team deliver world-class DNA-based diagnostic tests to detect diseases, or the genetic predisposition to diseases.”
D3 Technologies Ltd is a pioneer in trace level detection technologies based on the exploitation of Surface-Enhanced Raman Scattering (SERS) and Surface-Enhanced Resonance Raman Scattering (SERRS). By combining world-class nanometrology with unique Klarite® substrate technology, it serves a diverse range of fields including medical diagnostics, analytical applications, security and bio-defence, and forensic science. The Company is based in Glasgow, Scotland, and is part of the Renishaw Group, a world-leader in engineering, medical device and Raman spectroscopy technologies.